Hilde van der Staaij

Ms. Hilde van der Staaij

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
HSHilde van der Staaij
Hilde van der Staaij
ADAlbertine E. Donker
Albertine E. Donker
DBDirk Lodewijk Bakkeren
Dirk Lodewijk Bakkeren
JSJan M. J. I. Salemans
Jan M. J. I. Salemans
LMLisette A. A. Mignot-Evers
Lisette A. A. Mignot-Evers
DSDorine Swinkels
Dorine Swinkels
Pathogenic TMPRSS6 variants impairing matriptase-2 function result in inappropriately high hepcidin levels relative to body iron status, leading to iron refractory iron deficiency anemia (IRIDA). As diagnosing IRIDA can be challenging due to its genotypical and phenotypical heterogeneity, we assessed the transferrin saturation (TSAT)/hepcidin ratio to distinguish IRIDA from multi-causal iron deficiency anemia (IDA). We included 20 IRIDA patients from a registry for rare inherited iron disorders and then enrolled 39 controls with IDA due to other causes. Plasma hepcidin-25 levels were measured by standardized isotope dilution mass spectrometry. IDA controls had not received iron therapy in the last 3 months and C-reactive protein levels were <10.0 mg/L. IRIDA patients had significantly lower TSAT/hepcidin ratios compared to IDA controls, median 0.6%/nM (interquartile range, IQR, 0.4–1.1%/nM) and 16.7%/nM (IQR, 12.0–24.0%/nM), respectively. The area under the curve for the TSAT/hepcidin ratio was 1.000 with 100% sensitivity and specificity (95% confidence intervals 84–100% and 91–100%, respectively) at an optimal cut-off point of 5.6%/nM. The TSAT/hepcidin ratio shows excellent performance in discriminating IRIDA from TMPRSS6-unrelated IDA early in the diagnostic work-up of IDA provided that recent iron therapy and moderate-to-severe inflammation are absent. These observations warrant further exploration in a broader IDA population.

15 July 2024 in Archives of Disease in Childhood - Fetal and Neonatal Edition
Verified
Journal Article
Closed access
PDF file
HSHilde van der Staaij
Hilde van der Staaij
NHNadine M A Hooiveld
Nadine M A Hooiveld
CCCamila Caram-Deelder
Camila Caram-Deelder
SFSuzanne F Fustolo-Gunnink
Suzanne F Fustolo-Gunnink
KFKarin Fijnvandraat
Karin Fijnvandraat
Enrico LoprioreEnrico Lopriore
Enrico Lopriore
Objective: To describe the incidence of major bleeds according to different platelet counts in very preterm infants, and to explore whether this association is influenced by other risk factors for bleeding. Design: Observational cohort study. Setting: A Dutch tertiary care neonatal intensive care unit. Patients: All consecutive infants with a gestational age at birth <32 weeks admitted between January 2004 and July 2022. Exposure: Infants were stratified into nine groups based on their nadir platelet count (×109/L) during admission (<10, 10–24, 25–49, 50–99, 100–149, 150–199, 200–249, 250–299 and ≥300), measured before the diagnosis of a major bleed and before any platelet transfusion was administered. Main outcome measure: Incidence of major bleeds during admission. Logistic regression analysis was used to quantify the relationship between nadir platelet count and incidence of major bleeds. Results: Among 2772 included infants, 224 (8%) developed a major bleed. Of the infants with a major bleed, 92% (206/224) had a nadir platelet count ≥50×109/L. The incidence of major bleeds was 8% among infants with and without severe thrombocytopenia (platelet count <50×109/L), 18/231 (95% CI 5 to 12) and 206/2541 (95% CI 7 to 9), respectively. Similarly, after adjustment for measured confounders, there was no notable association between nadir platelet counts below versus above 50×109/L and the occurrence of major bleeds (OR 1.09, 95% CI 0.61 to 1.94). Conclusion: In very preterm infants, the vast majority of major bleeds occur in infants without severe thrombocytopenia.

31 August 2023 in Clinics in Perinatology
Verified
Journal Article
Closed access
HSHilde van der Staaij
Hilde van der Staaij
SSSimon J. Stanworth
Simon J. Stanworth
SFSusanna F. Fustolo-Gunnink
Susanna F. Fustolo-Gunnink

3 September 2026 in medRxiv
Verified
Preprint
Open access
PDF file
AHAntoine Honoré
Antoine Honoré
TRTill Rech
Till Rech
ASAlexandra Scrivens
Alexandra Scrivens
IBIvan Binotto
Ivan Binotto
CZCoen Zandvoort
Coen Zandvoort
TNThe Neonatal Transfusion Network
The Neonatal Transfusion Network
Background and Objectives: Preterm infants are commonly transfused, yet direct cardiorespiratory effects of red blood cell (RBC) transfusions remain poorly understood. We explored the feasibility of using multicentre electronic health data (EHD) to study such cardiorespiratory responses. Methods: Highly granular routine EHD were collected from preterm infants born <32 weeks gestational age at three European centres. Heart rate, oxygen saturation, and respiratory rate were evaluated 12 hours before and after the RBC transfusion. Results: A total of 321 transfusions in 164 infants were analysed. Overall, there was no significant change in the rate of bradycardia and apnoea following transfusion. Cardiorespiratory parameters varied substantially between infants; e.g. 20% of transfusions were associated with an unexpected, significant increase in heart rate. Respiratory rate and oxygen saturation exhibited similarly heterogenous patterns following transfusion. In sub-group analysis, the proportion of transfusions with increased heart rate was significantly higher within the first two weeks than later (32% vs 13%, p=0.0019). Conclusions: Multicentre EHD extraction allows to identify otherwise masked short-term effects of RBC transfusions on cardiorespiratory parameters, possibly indicating cardiac or pulmonary overload. Such effects may vary with adaptation to anaemia. Analysing EHD may ultimately enable personalized transfusion practice.